Rentschler Biopharma appoints Benedikt von Braunmuehl as Chief Executive Officer
September 19, 2023 05:00 ET
|
Rentschler Biopharma SE
Benedikt von Braunmuehl, a transformational leader with a 30-year track record in the global healthcare industry, is named CEO Rentschler Biopharma SECompany also announces appointment of Tom Roberts,...
Rentschler Biopharma’s ATMP facility in Stevenage, UK, receives MHRA approval
September 13, 2023 03:00 ET
|
Rentschler Biopharma SE
UK site now set for clinical production of adeno-associated virus (AAV) vectors for gene therapyHighly experienced team ready to support ATMP innovators at all stagesOffering comprehensive range of...
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
June 01, 2023 05:09 ET
|
Rentschler Biopharma SE
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
Rentschler Biopharma Receives Worcester Business Journal 2023 Manufacturing Excellence Award
April 27, 2023 10:00 ET
|
Rentschler Biopharma SE
Company presented with Workforce Development Award, recognizing partnership with MassBioEd and WPI to train people for biotech manufacturing positions Company honored at Worcester Business Journal...
Rentschler Biopharma’s service excellence recognized with CDMO Leadership Awards and Champion status
March 20, 2023 06:00 ET
|
Rentschler Biopharma SE
Rentschler Biopharma honored with four CDMO Leadership AwardsChampion status in the Compatibility category highlights outstanding cultural fit, project management and reputationThe prestigious awards...
Rentschler implements innovative learning program in collaboration with MassBioEd and WPI
December 07, 2022 09:00 ET
|
Rentschler Biopharma SE
LAUPHEIM, Germany and MILFORD, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is...
After seven years of accelerated growth at Rentschler Biopharma SE under his leadership as CEO, Dr. Frank Mathias to return to the Supervisory Board
November 21, 2022 11:30 ET
|
Rentschler Biopharma SE
Dr. Frank Mathias joined Rentschler Biopharma SE’s Supervisory Board in 2013 and was appointed Chief Executive Officer and Chairman of the Executive Board in April 2016. LAUPHEIM, Germany, Nov. 21,...
Rentschler Biopharma appoints Christiane Bardroff as Chief Operating Officer and Member of the Executive Board
November 16, 2022 04:00 ET
|
Rentschler Biopharma SE
Company increases focus on core operationsChristiane Bardroff to head global clinical and commercial manufacturing, engineering and technology operations, as well as production automation LAUPHEIM,...
Rentschler Biopharma appoints Mark Caswell as Vice President, Site Head for US Facility
August 18, 2022 09:03 ET
|
Rentschler Biopharma SE
LAUPHEIM, Germany and MILFORD, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals,...
Rentschler Biopharma adds highly experienced executive to team and provides update on progress at Rentschler ATMP
June 13, 2022 10:00 ET
|
Rentschler Biopharma SE
Company hires Kassim Kolia, as Vice President, Business Development to grow cell and gene therapy businessStevenage ATMP site projected to be client ready for process development in late 2022 ...